Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): Risk of graft rejection

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Nivolumab (Opdivo▼) and pembrolizumab (Keytruda▼) indicated for the treatment of malignant melanoma, non-small-cell lung cancer, and relapsed or refractory classical Hodgkin’s lymphoma are immune checkpoint inhibitors that block the activity of a protein programmed death receptor 1 (PD-1).

Reports in the post-marketing setting in patients treated with programmed death receptor 1 (PD-1) inhibitors concluded that nivolumab and pembrolizumab may increase the risk of rejection in organ transplant recipients. Of the 5 patients receiving nivolumab, 3 had kidney transplant rejection, 1 had corneal transplant rejection, and 1 had skin graft rejection. Four patients receiving pembrolizumab h...